Benzolactam growth hormone secretagogues

Drugs of the Future

Volumn 21, Issue 3, 1996, Pages 273-281

  DeVita, Robert J ^a   Wyvratt, Matthew J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO N [2 BENZYLOXY 1 (1,2 DIHYDRO 1 METHANESULFONYLSPIRO[3H INDOLE 3,4' PIPERIDIN 1' YL]CARBONYL)ETHYL] 2 METHYLPROPIONAMIDE; 3 AMINO 3 METHYL N [2,3,4,5 TETRAHYDRO 2 OXO 1 [[2' (1H TETRAZOL 5 YL) 1,1' BIPHENYL 4 YL]METHYL] 1H 1 BENZAZEPIN 3 YL]BUTANAMIDE; GROWTH HORMONE; GROWTH HORMONE DERIVATIVE; HUMAN GROWTH HORMONE; IBUTAMOREN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; CONTROLLED STUDY; DOG; GROWTH HORMONE DEFICIENCY; HYPOPHYSIS CELL; NONHUMAN; RAT; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0029898430     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1996.021.03.353289     Document Type: Review

References (45)

1. Strobl, J.S., Thomas, M.J. Human growth hormone. Pharmacol Rev 1994, 46: 1-34.
2. Chipman, J.J. Recent advances in hGH clinical research J Pediatr Endocrinol 1993, 6: 325-8.
3. Jorgensen, J O.L, Christiansen, J.S Growth hormone therapy. Brave new senescence: GH in adults. Nature 1993, 341: 1247-8.
4. Sacca, L., Cittadini, A., Fazio, S. Growth hormone and the heart. Endocrine Rev 1994, 15: 555-73.
5. Rudman, D , Feller, A.G., Nagraj, H.S. et al. Effects of human growth hormone in men over 60 years old New Engl J Med 1990, 323: 1-6.
6. Schoen, W.R., Wyvratt, M.J., Smith, R.G. Growth hormone secretagogues In: Annual Reports in Medicinal Chemistry. Bristol, J A. (Ed.). Academic Press: Orlando 1993, 28: 177-86.
7. Thorner, M.O On the discovery of growth hormone-releasing hormone. Acta Pediatr 1993, 388 (Suppl.): 2-7.
8. Low, L.C.K. Growth hormone-releasing hormone: Clinical studies and therapeutic aspects. Neuroendocrmology 1991, 53 (Suppl 1): 37-40.
9. Guillemin, R., Brazeau, P., Bohlem, P., Esch, F., Ling, N., Wehrenberg, W.B., Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science 1982, 218: 585-7.
10. Bowers, C Y., Chang, J., Momany, F , Folkers, K. Effects of the enkephalins and enkephalin analogs on release of pituitary hormones in vitro. In: Molecular Endocrinology. MacIntyne, I. (Ed.). Elsevier/North Holland Biomedical Press: Amsterdam 1977, 287-92.
11. Codd, E.E., Shu, A.Y., Walker, R.F. Binding of a growth hormone releasing hexapeptide to specific hypothalamic and pituitary binding sites. Neuropharmacology 1989, 28: 1139-44.
12. Bowers, C.Y., Sartor, A.O., Reynolds, G.A., Badger, T.M. On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology 1991, 128: 2027-35.
13. Dickson, S.L. Evidence for a central site and mechanism of action of growth hormone releasing peptide (GHRP-6). Proc Int Symp Growth Hormone Secretagogues (Dec 8-11, 1994, St. Petersburg Beach, FL) 1996, in press.
14. Smith, R.G., Cheng, K., Pong, S.-S. et al. Mechanism of action of GHRP-6 and nonpeptidyl growth hormone secretagogues. Proc Int Symp Growth Hormone Secretagogues (Dec 8-11, 1994, St. Petersburg, FL) 1995, in press.
15. Smith, R.G., Pong, S.-S., Hickey, G. et al. Modulation of pulsatile GH release through a novel receptor in hypothalamus and pituitary gland. Recent Prog Hormone Res 1996, in press.
16. Bowers, C.Y., Momany, F., Reynolds, G.A., Chang, D., Hong, A., Chang, K. Structure activity relationships of a synthetic pentapeptide that specifically releases growth hormone in vitro. Endocrinology 1980, 106: 663-7.
17. Momany, F.A., Bowers, C.Y., Reynolds, G.A., Chang, D., Hong, A., Newlander, K. Design, synthesis, and biological activity of peptides which release growth hormone in vitro. Endocrinology 1981, 108: 31-9.
18. Momany, F.A., Bowers, C.Y., Reynolds, G A., Hong, A., Newlander, K. Conformational energy studies and in vitro and in vivo activity data on growth hormone-releasing peptides. Endocrinology 1984, 114: 1531-6.
19. Bowers, C.Y. GH releasing peptides - Structure and kinetics. J Pediatr Endocrinol 1993, 6: 21-31.
20. Laron, A. Growth hormone secretagogues, clinical experience and therapeutic potential. Drugs 1995, 50: 595-601.
21. 2 on growth hormone (GH)-releasing factor stimulated GH release and intracellular adenosine-3′,5′monophosphate accumulation in rat primary pituitary cell culture. Endocrinology 1989, 124: 2791-8.
22. Smith, R.G., Cheng, K., Schoen, W.R. et al. A nonpeptidyl growth hormone secretagogue. Science 1993, 260: 1640-3.
23. Schoen, W.R., Pisano, J.M., Prendergast, K. et al. A novel 3-substituted benzazepmone growth hormone secretagogue (L-692,429). J Med Chem 1994, 37: 897-906.
24. Bowers, C.Y. Editorial. On a peptidomimetic growth hormone-releasing peptide. J Clin Endocrinol Metab 1994, 79: 940-2.
25. Wyvratt, M. Non-peptidyl growth hormone secretagogues. Proc Int Symp Growth Hormone Secretagogues (Dec. 8-11, 1994, St. Petersburg, FL) 1996, in press.
26. Pong, S.-S., Chaung, L.-Y., Dean, D.C., Nargund, R.P., Patchett, A.A., Smith, R.G. Identification of a new G-protein-linked receptor for growth hormone secretagogues. Mol Endocrinol 1996, 10: 57-61.
27. DeVita, R J., Schoen, W.R , Doldouras, G.S et al. Heterocyclic analogs of the benzolactam nucleus of the non-peptidic growth hormone secretagogue L-692,429. BioMed Chem Lett 1995, 5: 1281-6.
28. Parsons, W.H., Patchett, A.A., Holloway, M.K. et al. Cholecystokinin antagonists. Synthesis and biological evaluation of 3-substituted benzolactams. J Med Chem 1989, 32: 1681-5.
29. Bock, M.G., DiPardo, R.M., Veber, D F. et al. Benzolactams as non-peptide cholecystokinin receptor ligands. BioMed Chem Lett 1993, 3: 871-4.
30. Schoen, W.R., Ok, D., DeVita, R.J. et al. Structure activity relationships in the amino acid side-chain of L-692,429. BioMed Chem Lett 1994, 4: 1117-22.
31. Ok, D., Schoen, W.R , Hodges, P. et al. Structure activity relationships of the nonpeptidyl growth hormone secretagogue L-692,429. BioMed Chem Lett 1994, 4: 2709-14.
32. DeVita, R.J., Schoen, W R., Ok, D. et al. Benzolactam growth hormone secretagogues: Replacements for the 2′-tetrazole moiety of L-692,429. BioMed Chem Lett 1994, 4: 1807-12.
33. DeVita, R.J., Schoen, W.R., Fisher, M.H. et al. Benzolactam growth hormone secretagogues: Carboxamides as replacements forthe 2′-tetrazole moiety of L692,429. BioMed Chem Lett 1994, 4: 2249-54.
34. Hickey, G., Jacks, J., Judith, F. Efficacy and specificity of L-692,429, a novel nonpeptide growth hormone secretagogue in beagles. Endocrinology 1994, 134: 695-701.
35. Gertz, B.J., Barrett, U.S., Eisenhandler, R. et al. Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone releasing peptide. J Clin Endocrinol Metab 1993, 77: 1393-7.
36. Aloi, J.A., Gertz. B.J., Hartman, M.L. et al. Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects J Clin Endocrinol Metab 1994, 79: 943-9.
37. Gertz, B.J., Sciberras, D.G., Yogendran, L et al. L-692,429, a nonpeptide growth hormone (GH) secretagogue, reverses glucocorticoid suppression of GH secretion. J Clin Endocrinol Metab 1994, 79: 745-9.
38. Horber, F.F., Haymond, M.W. Human growth hormone prevents the protein catabolic side effects of prednisone in humans. J Clin Invest 1990, 86. 265-72.
39. 4) levels in beagles. J Endocrinol 1994, 143: 399-406.
40. Chang, C.H., Rickes, E.L., Marsilio, F. et al. Activity of a novel non-peptidyl growth hormone secretagogue L-700, 653 in swine. Endocrinology 1995, 136: 1065-71.
41. Cheng, K., Chan, W.W.-S., Butler, B. et al. Stimulation of growth hormone release from rat primary pituitary cells by L-692,429, a novel non-peptidyl growth hormone secretagogue. Endocrinology 1993, 132: 2729-31.
42. Hickey, G. J., Drisko, J., Faidley, T. et al. Mediation by the central nervous system is critical to the in vivo activity of the GH secretagogue L-692,585. J Endocrinol 1996, 148: 371-80.
43. Dickson, S.L., Leng, G , Dyball, R.E.J, Smith, R.G. Central actions of peptide and nonpeptide growth hormone secretagogues in the rat. Neuroendocrinology 1995, 61: 36-43.
44. Patchett, A.A., Nargund, R.P., Tata, J.R. et al. Design and biological activites of L-163,191 (MK-0677): A potent orally active growth hormone secretagogue. Proc Natl Acad Sci USA 1995, 92: 7001-5.
45. Evans, B.E., Rittle, K.E., Bock, M.G. et al. Methods for drug discovery: Development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem 1988, 31: 2235-46.